Breaking News Instant updates and real-time market news.

REGN

Regeneron

$376.40

5.44 (1.47%)

, SNY

Sanofi

$44.17

-0.62 (-1.38%)

15:28
04/21/17
04/21
15:28
04/21/17
15:28

EMA's CHMP issues positive opinion on Kevzara in rheumatoid arthritis

The Committee for Medicinal Products for Human Use, or CHMP, of the EMA announced it has adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kevzara, intended for the treatment of rheumatoid arthritis.

REGN

Regeneron

$376.40

5.44 (1.47%)

SNY

Sanofi

$44.17

-0.62 (-1.38%)

  • 24

    Apr

  • 03

    May

REGN Regeneron
$376.40

5.44 (1.47%)

03/29/17
SBSH
03/29/17
NO CHANGE
Target $420
SBSH
Buy
Citi sees upside to consensus expectations for Dupixent launch
Citi analyst Robyn Karnauskas believes Regeneron Pharmaceuticals is taking a smart approach to the Dupixent launch by going after the sickest moderate to severe atopic dermatitis patients. A lack of payer pushback, which is the biggest investor concern, could make the launch look better than the street expectations of $138M for 2017, Karnauskas tells investors in a research note. She keeps a Buy rating on Regeneron with a $420 price target.
03/29/17
FBCO
03/29/17
NO CHANGE
Target $485
FBCO
Outperform
Credit Suisse sees upside to Regeneron Dupixent if favorable payer environment
After FDA approved Regeneron (REGN) and Sanofi's (SNY) Dupixent, Credit Suisse analyst Alethia Young says that the pricing was higher than her expectations, but thinks that the peak opportunity is roughly around the same, remaining unchanged at $4.7B in 2025. Additionally, the analyst thinks that Regeneron/Sanofi upfront effort with payers may help early days of launch. She reiterates an Outperform rating and $485 price target on Regeneron's shares.
03/29/17
UBSW
03/29/17
NO CHANGE
Target $446
UBSW
Buy
Regeneron target raised to $446 on higher than expected Dupixent pricing at UBS
UBS analyst Carter Gould noted that on the call related to Dupixent's approval for atopic dermatitis Regeneron (REGN) and Sanofi (SNY) said that the drug's annual $37K gross price was expected to translate into a net price in the "low $30K range" annually, which is above his prior estimate near $24K. Along with raising his annual net pricing assumption, Gould increased his peak sales estimate for Dupixent in atopic dermatitis to $3.1B from $2.8B and raised his price target on Regeneron to $446 from $435 while keeping a Buy rating on the stock.
03/30/17
WEDB
03/30/17
NO CHANGE
Target $33
WEDB
Outperform
AnaptysBio price target raised to $33 from $28 at Wedbush
Wedbush analyst David Nierengarten raised his price target for AnaptysBio (ANAB) to $33 from $28 saying that Regeneron (REGN) and Sanofi's (SNY) Dupixent price suggests that higher pricing for the former's ANB020 could be achievable. The analyst reiterates an Outperform rating on AnaptysBio's shares.
SNY Sanofi
$44.17

-0.62 (-1.38%)

04/07/17
04/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lamb Weston (LW) downgraded to Hold from Buy at Stifel with analyst Christopher Growe citing the 44% up move in shares since he launched coverage in November 2016. 2. AstraZeneca (AZN), Novo Nordisk (NVO), Sanofi (SNY), Roche (RHHBY), and Grifols (GRFS) were downgraded to Reduce from Hold at HSBC. 3. AECOM (ACM) downgraded to Neutral from Outperform at Baird with analyst Andrew Wittmann saying the company filed an amendment to its credit agreement suggesting likely risk to 2017 earnings, as the filing implies the company would have breached its leverage covenant without an amendment. The analyst is also cautious given the relative obscurity of the filing. Wittmann lowered his price target to $40 from $45 on AECOM shares. 4. Arista Networks (ANET) downgraded to Neutral on valuation at Nomura with analyst Jeffrey Kvaal citing valuation. 5. Maximus (MMS) downgraded to Hold from Buy at Canaccord analyst Richard Close citing expectations of a slow near-term RFP and contract award environment given the recent Trump administration transition. click here.
04/07/17
RAJA
04/07/17
NO CHANGE
RAJA
Strong Buy
Flexion CMO hiring adds to Raymond James' skepticism of takeover speculation
Raymond James analyst Elliot Wilbur previously said he was skeptical of media-driven speculation that Sanofi (SNY) was preparing to bid for Flexion (FLXN), but he views the appointment of Yamo Deniz, another former Sanofi executive, as Flexion's chief medical officer as one more reason to doubt the rumor. Deniz "joins a growing roster of hires" from Sanofi and Wilbur does not believe these individuals, who "would have the best firsthand knowledge of exactly what the buzz is on Zilretta from the Sanofi perspective," would join Flexion simply to rejoin Sanofi again. While he thinks "some deflation" of the takeout premium in the stock could follow this hiring, Wilbur keeps a Strong Buy rating on Flexion shares.
04/11/17
JPMS
04/11/17
UPGRADE
JPMS
Neutral
Sanofi upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Richard Vosser upgraded Sanofi to Neutral saying he no longer sees downside to consensus estimates. The pressure on the diabetes business now seems largely reflected in estimates, Vosser tells investors in a research note. The analyst raised his price target for the shares to EUR 87 from EUR 71.
04/11/17
04/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Conviction Buy from Buy at Goldman with analyst Drew Borst saying that the success of "Beauty and the Beast" has increased his confidence in his forecast that FY18 EPS growth will accelerate given the company's promising film slate and its read-through to consumer products. He also sees accelerating profit growth at ESPN given normalizing NBA costs and predicts record results for the Theme Parks segment. Borst keeps a $138 price target on Disney shares. 2. McDonald's (MCD) upgraded to Buy from Neutral at Cleveland Research. 3. Yelp (YELP) upgraded to Overweight from Sector Weight at Pacific Crest with analyst Brad Erickson saying his checks with local ad customers indicate Yelp's core franchise is healthy and appears insulated from larger competitors like Google (GOOG, GOOGL) and Facebook (FB). 4. Toll Brothers (TOL) upgraded to Outperform from Sector Perform at RBC Capital with analyst Robert Wetenhall citing "solid demand,strong execution, proven management, a strong luxury housing business, and consistent earnings." 5. Sanofi (SNY) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he no longer sees downside to consensus estimates. The pressure on the diabetes business now seems largely reflected in estimates, Vosser tells investors in a research note. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

OAK

Oaktree Capital

08:46
04/27/17
04/27
08:46
04/27/17
08:46
Earnings
Oaktree Capital reports Q1 adj. EPS 86c, consensus 77c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

UAA

Under Armour

$19.71

0.18 (0.92%)

, CTL

CenturyLink

$25.87

-0.06 (-0.23%)

08:46
04/27/17
04/27
08:46
04/27/17
08:46
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

UAA

Under Armour

$19.71

0.18 (0.92%)

CTL

CenturyLink

$25.87

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 31

    May

CNMD

CONMED

$48.13

0.93 (1.97%)

08:45
04/27/17
04/27
08:45
04/27/17
08:45
Recommendations
CONMED analyst commentary  »

CONMED price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

ALKS

Alkermes

$57.13

0.13 (0.23%)

08:45
04/27/17
04/27
08:45
04/27/17
08:45
Hot Stocks
Alkermes says NDA for ALKS 5461 on track for this year »

Alkermes says it is on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

  • 08

    Jun

MGM

MGM Resorts

$29.79

0.44 (1.50%)

08:45
04/27/17
04/27
08:45
04/27/17
08:45
Hot Stocks
MGM Resorts reports MGM China revenues up 7% to $502M »

Key first quarter results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

08:45
04/27/17
04/27
08:45
04/27/17
08:45
General news
FX Action: The dollar »

FX Action: The dollar…

AAL

American Airlines

$46.40

-0.21 (-0.45%)

08:44
04/27/17
04/27
08:44
04/27/17
08:44
Technical Analysis
American Airlines trades down after earnings, downgrade »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WSM

Williams-Sonoma

$54.66

0.03 (0.05%)

08:43
04/27/17
04/27
08:43
04/27/17
08:43
Hot Stocks
Williams-Sonoma launches food collaboration with Trisha Yearwood »

Williams Sonoma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

FFIV

F5 Networks

$137.30

-0.89 (-0.64%)

08:43
04/27/17
04/27
08:43
04/27/17
08:43
Recommendations
F5 Networks analyst commentary  »

F5 Networks should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPWR

Monolithic Power

$93.71

-2.5 (-2.60%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Recommendations
Monolithic Power analyst commentary  »

Monolithic Power price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$1.87

-0.1399 (-6.96%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Hot Stocks
Cellectar says radiotherapeutic PDCS demonstrates increased survival benefit »

Cellectar Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$29.79

0.44 (1.50%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Earnings
MGM Resorts reports Q1 EPS 36c, consensus 29c »

Reports Q1 revenue less…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

DLX

Deluxe

$71.85

0.26 (0.36%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Earnings
Deluxe narrows FY17 EPS view to $5.15-$5.30 from $5.10-$5.30, consensus $5.21 »

Narrows FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

ALKS

Alkermes

$57.13

0.13 (0.23%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Hot Stocks
Alkermes sees FDA meeting on ALKS 5461 in late June, early July »

Alkermes said on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

  • 08

    Jun

UPS

UPS

$107.62

0.26 (0.24%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Hot Stocks
UPS says plans to announce additional strategic moves in coming weeks »

Comments from Q1 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 04

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

RMTI

Rockwell Medical

$8.64

0.28 (3.35%)

08:41
04/27/17
04/27
08:41
04/27/17
08:41
Hot Stocks
Rockwell Medical to present on Triferic at Congress of IBIS »

Rockwell Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDSO

Medidata

$67.14

3.8 (6.00%)

08:41
04/27/17
04/27
08:41
04/27/17
08:41
Recommendations
Medidata analyst commentary  »

Medidata price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

TEUM

Pareteum

$0.71

0.0084 (1.20%)

08:40
04/27/17
04/27
08:40
04/27/17
08:40
Hot Stocks
Pareteum's cloud platform selected by THYNGS »

Pareteum's Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLX

Deluxe

$71.85

0.26 (0.36%)

08:40
04/27/17
04/27
08:40
04/27/17
08:40
Earnings
Deluxe sees Q3 adj. EPS $1.20-$1.25 »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

08:40
04/27/17
04/27
08:40
04/27/17
08:40
General news
U.S. initial jobless claims rose 14k »

U.S. initial jobless…

DLX

Deluxe

$71.85

0.26 (0.36%)

08:39
04/27/17
04/27
08:39
04/27/17
08:39
Earnings
Deluxe sees Q2 adj. EPS $1.23-$1.28, consensus $1.24 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

TWTR

Twitter

$15.82

1.16 (7.91%)

08:39
04/27/17
04/27
08:39
04/27/17
08:39
Recommendations
Twitter analyst commentary  »

Twitter ad revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SINO

Sino-Global

$3.03

0.08 (2.71%)

08:39
04/27/17
04/27
08:39
04/27/17
08:39
Hot Stocks
Sino-Global signs cooperation agreement with Ningbo Xinyang Shipping »

Sino-Global signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLX

Deluxe

$71.85

0.26 (0.36%)

08:38
04/27/17
04/27
08:38
04/27/17
08:38
Earnings
Deluxe reports Q1 EPS $1.25, consensus $1.15 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

DGLY

Digital Ally

$4.25

0.25 (6.25%)

08:37
04/27/17
04/27
08:37
04/27/17
08:37
Hot Stocks
Digital Ally receives order for airport shuttle bus fleet video systems upgrade »

Digital Ally announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.